Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-12 |
2024-06 |
0 |
N/A |
N/A |
N/A |
2024-05-13 |
2024-03 |
0 |
-0.08 |
N/A |
N/A |
2024-03-28 |
2023-12 |
0 |
-0.1 |
N/A |
N/A |
2023-11-14 |
2023-09 |
-0.44 |
-0.33 |
0.11 |
25.00% |
2023-08-14 |
2023-06 |
-0.43 |
-0.48 |
-0.05 |
-11.63% |
2023-05-11 |
2023-03 |
-0.36 |
-0.5 |
-0.14 |
-38.89% |
Date |
Firm |
Action |
From |
To |
2023-08-28 |
Citigroup |
Upgrade |
Neutral |
Neutral |
2023-08-15 |
HC Wainwright & Co. |
Downgrade |
Buy |
Neutral |
2023-08-09 |
Piper Sandler |
Downgrade |
Overweight |
Neutral |
2023-07-16 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-03-21 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-02-20 |
Piper Sandler |
Upgrade |
|
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2022-07-17 |
ALLEVA LAWRENCE M |
Director |
10.37K |
Stock Gift |
2024-03-27 |
ALTAMONT PHARMACEUTICAL HOLDINGS LLC |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2023-03-15 |
BACHLEDA MARK |
Officer |
11.00K |
Purchase |
2022-11-20 |
BEARDSLEY ROBERT A |
Chief Operating Officer |
108.19K |
Conversion of Exercise of derivative security |
2023-03-12 |
DEGNAN CHRISTOPHER |
Chief Financial Officer |
10.00K |
Purchase |
2021-08-31 |
HOLMLUND JON T |
Officer |
0.00 |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Sofinnova Investments, Inc. |
3.08M |
9.62M |
7.02% |
2023-06-29 |
Novo Holdings A/S |
2.10M |
6.55M |
4.78% |
2023-06-29 |
Sectoral Asset Management, Inc. |
2.01M |
6.26M |
4.56% |
2023-06-29 |
Alyeska Investment Group, L.p. |
1.70M |
5.30M |
3.87% |
2023-06-29 |
Blackstone Inc |
1.68M |
5.24M |
3.82% |
2023-06-29 |
Vanguard Group Inc |
1.43M |
4.46M |
3.25% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.05M |
3.28M |
2.40% |
2023-06-29 |
Tekla Healthcare Opportunities Fund |
314.43K |
981.02K |
0.72% |
2023-06-29 |
Vanguard Extended Market Index Fund |
317.98K |
992.09K |
0.72% |
2023-06-29 |
Tekla Healthcare Investors |
296.46K |
924.96K |
0.67% |
2023-06-29 |
Tekla World Healthcare Fund |
161.71K |
504.53K |
0.37% |
2023-06-29 |
Tekla Life Sciences Investors |
125.77K |
392.41K |
0.29% |